» Articles » PMID: 39595536

Oxidative Phosphorylation As a Predictive Biomarker of Oxaliplatin Response in Colorectal Cancer

Overview
Journal Biomolecules
Publisher MDPI
Date 2024 Nov 27
PMID 39595536
Authors
Affiliations
Soon will be listed here.
Abstract

Oxaliplatin is successfully used on advanced colorectal cancer to eradicate micro-metastasis, whereas its benefits in the early stages of colorectal cancer remains controversial since approximately 30% of patients experience unexpected relapses. Herein, we evaluate the efficacy of oxidative phosphorylation as a predictive biomarker of oxaliplatin response in colorectal cancer. We found that non-responding patients exhibit low oxidative phosphorylation activity, suggesting a poor prognosis. To reach this conclusion, we analyzed patient samples of individuals treated with oxaliplatin from the GSE83129 dataset, and a set of datasets validated using ROCplotter, selecting them based on their response to the drug. By analyzing multiple oxaliplatin-resistant and -sensitive cell lines, we identified oxidative phosphorylation KEGG pathways as a valuable predictive biomarker of oxaliplatin response with a high area under the curve (AUC = 0.843). Additionally, some oxidative phosphorylation-related biomarkers were validated in primary- and metastatic-derived tumorspheres, confirming the results obtained in silico. The low expression of these biomarkers is clinically relevant, indicating poor prognosis with decreased overall and relapse-free survival. This study proposes using oxidative phosphorylation-related protein expression levels as a predictor of responses to oxaliplatin-based treatments to prevent relapse and enable a more personalized therapy approach. Our results underscore the value of oxidative phosphorylation as a reliable marker for predicting the response to oxaliplatin treatment in colorectal cancer.

Citing Articles

Analysis of ROMO1 Expression Levels and Its Oncogenic Role in Gastrointestinal Tract Cancers.

Yaman S, Akidan O, Vatansever M, Misir S, Yaman S Curr Issues Mol Biol. 2024; 46(12):14394-14407.

PMID: 39727991 PMC: 11674390. DOI: 10.3390/cimb46120863.


Inhibiting de novo lipogenesis identifies a therapeutic vulnerability in therapy-resistant colorectal cancer.

Jog E, Jainarayanan A, La Ferlita A, Chakraborty A, Dalwai A, Yahya S Redox Biol. 2024; 79():103458.

PMID: 39705849 PMC: 11729006. DOI: 10.1016/j.redox.2024.103458.

References
1.
Yang A, Fan F, Camp E, Van Buren G, Liu W, Somcio R . Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006; 12(14 Pt 1):4147-53. DOI: 10.1158/1078-0432.CCR-06-0038. View

2.
Guerra F, Arbini A, Moro L . Mitochondria and cancer chemoresistance. Biochim Biophys Acta Bioenerg. 2017; 1858(8):686-699. DOI: 10.1016/j.bbabio.2017.01.012. View

3.
Zhou Y, Xia L, Wang H, Oyang L, Su M, Liu Q . Cancer stem cells in progression of colorectal cancer. Oncotarget. 2018; 9(70):33403-33415. PMC: 6161799. DOI: 10.18632/oncotarget.23607. View

4.
Vyas S, Zaganjor E, Haigis M . Mitochondria and Cancer. Cell. 2016; 166(3):555-566. PMC: 5036969. DOI: 10.1016/j.cell.2016.07.002. View

5.
Sadanandam A, Lyssiotis C, Homicsko K, Collisson E, Gibb W, Wullschleger S . A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013; 19(5):619-25. PMC: 3774607. DOI: 10.1038/nm.3175. View